Antimicrobial Resistance and Characteristics of Eradication Therapy of Helicobacter pylori in Japan: A Multi-Generational Comparison

Helicobacter

Volumn 19, Issue 3, 2014, Pages 214-220

  Okamura, Takuma ^a   Suga, Tomoaki ^a   Nagaya, Tadanobu ^a   Arakura, Norikazu ^b   Matsumoto, Takehisa ^b   Nakayama, Yoshiko ^a   Tanaka, Eiji ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Antibiotic resistance; Eradication therapy; Helicobacter pylori; Young patient

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BLEPHAREDEMA; CHILD; CHRONIC GASTRITIS; COMPARATIVE STUDY; DIARRHEA; DYSPEPSIA; ERADICATION THERAPY; EYE DISEASE; FEMALE; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INCIDENCE; JAPAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; SCHOOL CHILD; STOMACH CANCER; TASTE DISORDER; VERY ELDERLY; YOUNG ADULT; ADVERSE DRUG REACTION; AGE; DRUG COMBINATION; DRUG EFFECTS; DRUG THERAPY; HELICOBACTER INFECTIONS; ISOLATION AND PURIFICATION; MICROBIOLOGY; PROCEDURES; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; JAPAN; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899081061     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12124     Document Type: Article

References (42)

1. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
2. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008;372:392-7.
3. Asaka M. A new approach for elimination of gastric cancer deaths in Japan. Int J Cancer 2013;132:1272-6.
4. Nozaki K, Shimizu N, Ikehara Y, et al. Effect of early eradication on Helicobacter pylori-related gastric carcinogenesis in Mongolian gerbils. Cancer Sci 2003;94:235-9.
5. Kobayashi I, Murakami K, Kato M, et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol 2007;45:4006-10.
6. Kato S, Fujimura S. Primary antimicrobial resistance of Helicobacter pylori in children during the past 9 years. Pediatr Int 2010;52:187-90.
7. Sasaki M, Ogasawara N, Utsumi K, et al. Changes in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin. J Clin Biochem Nutr 2010;47:53-8.
8. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-81.
9. Kobayashi I, Muraoka H, Saika T, et al. Micro-broth dilution method with air-dried microplate for determining MICs of clarithromycin and amoxycillin for Helicobacter pylori isolates. J Med Microbiol 2004;53:403-6.
10. Japan Society for Chemotherapy. Antimicrobial Susceptibility Subcommittee on Helicobacter pylori MIC breakpoints for clarithromycin and amoxicillin. Jpn Soc Chemother 2000;48:561-7.
11. Glupczynski Y, Megraud F, Lopez-Brea M, et al. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001;20:820-3.
12. Onder G, Aydin A, Akarca U, et al. High Helicobacter pylori resistance rate to clarithromycin in Turkey. J Clin Gastroenterol 2007;41:747-50.
13. Saracino IM, Zullo A, Holton J, et al. High prevalence of primary antibiotic resistance in Helicobacter pylori isolates in Italy. J Gastrointestin Liver Dis 2012;21:363-5.
14. Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013;62:34-42.
15. Tolia V, Brown W, El-Baba M, et al. Helicobacter pylori culture and antimicrobial susceptibility from pediatric patients in Michigan. Pediatr Infect Dis J 2000;19:1167-71.
16. Lopes AI, Oleastro M, Palha A, et al. Antibiotic-resistant Helicobacter pylori strains in Portuguese children. Pediatr Infect Dis J 2005;24:404-9.
17. Koletzko S, Richy F, Bontems P, et al. Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut 2006;55:1711-6.
18. Taneike I, Goshi S, Tamura Y, et al. Emergence of clarithromycin-resistant Helicobacter pylori (CRHP) with a high prevalence in children compared with their parents. Helicobacter 2002;7:297-305.
19. Cuadrado-Lavin A, Salcines-Caviedes JR, Carrascosa MF, et al. Antimicrobial susceptibility of Helicobacter pylori to six antibiotics currently used in Spain. J Antimicrob Chemother 2012;67:170-3.
20. Nahar S, Mukhopadhyay AK, Khan R, et al. Antimicrobial susceptibility of Helicobacter pylori strains isolated in Bangladesh. J Clin Microbiol 2004;42:4856-8.
21. Kim JM, Kim JS, Jung HC, et al. Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob Agents Chemother 2004;48:4843-7.
22. Eisig JN, Silva FM, Barbuti RC, et al. Helicobacter pylori antibiotic resistance in Brazil: clarithromycin is still a good option. Arq Gastroenterol 2011;48:261-4.
23. Su P, Li Y, Li H, et al. Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China. Helicobacter 2013;18:274-9.
24. An B, Moon BS, Kim H, et al. Antibiotic Resistance in Helicobacter pylori Strains and its Effect on H. pylori Eradication Rates in a Single Center in Korea. Ann Lab Med 2013;33:415-9.
25. Vilaichone RK, Gumnarai P, Ratanachu-Ek T, et al. Nationwide survey of Helicobacter pylori antibiotic resistance in Thailand. Diagn Microbiol Infect Dis 2013;77:346-9.
26. Kato M, Yamaoka Y, Kim JJ, et al. Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother 2000;44:2214-6.
27. Ueki N, Miyake K, Kusunoki M, et al. Impact of quadruple regimen of clarithromycin added to metronidazole-containing triple therapy against Helicobacter pylori infection following clarithromycin-containing triple-therapy failure. Helicobacter 2009;14:91-9.
28. Seo JH, Jun JS, Yeom JS, et al. Changing pattern of antibiotic resistance of Helicobacter pylori in children during 20 years in Jinju, South Korea. Pediatr Int 2013;55:332-6.
29. Loffeld RJ, Fijen CA. Antibiotic resistance of Helicobacter pylori: a cross-sectional study in consecutive patients, and relation to ethnicity. Clin Microbiol Infect 2003;9:600-4.
30. Reva I, Takano T, Higuchi W, et al. Virulence genotypes and drug resistance of Helicobacter pylori from Vladivostok, Russia: another feature in the Far East. Microbiol Immunol 2012;56:198-202.
31. Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009;24:1587-600.
32. Kupcinskas L, Rasmussen L, Jonaitis L, et al. Evolution of Helicobacter pylori susceptibility to antibiotics during a 10-year period in Lithuania. APMIS 2013;121:431-6.
33. Cosme A, Montes M, Martos M, et al. Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori. Clin Microbiol Infect 2013;19:379-83.
34. McNulty CA, Lasseter G, Shaw I, et al. Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered? Aliment Pharmacol Ther 2012;35:1221-30.
35. Alarcon T, Domingo D, Lopez-Brea M. Antibiotic resistance problems with Helicobacter pylori. Int J Antimicrob Agents 1999;12:19-26.
36. Wermeille J, Cunningham M, Dederding JP, et al. Failure of Helicobacter pylori eradication: is poor compliance the main cause? Gastroenterol Clin Biol 2002;26:216-9.
37. Furuta T, Shirai N, Sugimoto M, et al. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005;20:153-67.
38. Murakami K, Fujioka T, Okimoto T, et al. Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy. Int J Antimicrob Agents 2002;19:67-70.
39. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007;26:343-57.
40. Murakami K, Sato R, Okimoto T, et al. Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment Pharmacol Ther 2003;17:119-23.
41. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007;12:275-8.
42. Kato S, Konno M, Maisawa S, et al. Results of triple eradication therapy in Japanese children: a retrospective multicenter study. J Gastroenterol 2004;39:838-43.